116 chapter 2 Table 7. Estimated pooled test performance of BRAF mutation analysis in Bethesda IV thyroid nodules ni Bethesda IV test + test - test ? nH (%) TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Moses 2010 110 3 107 110 (100%) 3 0 26 81 26% 10 (2-27) 100 (96-100) 19.13 (1.02-359.59) 0.89 (0.78-1.01) Nikiforov 2011 214 2 212 214 (100%) 2 0 56 156 27% 3 (0-12) 100 (98-100) 13.31 (0.65-273.07) 0.96 (0.91-1.01) Patel 2011 20 0 20 20 (100%) 0 0 11 9 55% 0 (0-28) 100 (66-100) 0.83 (0.02-38.35) 1.01 (0.84-1.21) Yeo 2011 3 0 3 3 (100%) 0 0 1 2 33% 0 (0-98) 100 (16-100) 1.50 (0.05-49.07) 0.90 (0.35-2.32) Kang 2012 9 0 9 9 (100%) 0 0 4 5 44% 0 (0-60) 100 (48-100) 1.20 (0.03-50.31) 0.98 (0.67-1.43) Kloos 2013 70 1 69 70 (100%) 1 0 18 51 27% 5 (0-26) 100 (93-100) 7.80 (0.33-183.63) 0.93 (0.82-1.06) Koh 2013 5 0 5 5 (100%) 0 0 1 4 20% 0 (0-98) 100 (40-100) 2.50 (0.07-87.95) 0.83 (0.36-1.95) Ohori 2013 424 7 377 40 384 (100%) 7 0 107 270 27% 6 (3-12) 100 (99-100) 35.35 (2.04-613.77) 0.94 (0.89-0.98) BeaudenonHuibregtse 2014 38 0 38 19 (50%) 0 0 6 13 16% 0 (0-46) 100 (75-100) 2.00 (0.04-90.62) 0.96 (0.77-1.21) Danilovic 2014 20 4 16 20 (100%) 4 0 3 13 35% 57 (18-90) 100 (75-100) 15.75 (0.97-256.33) 0.45 (0.21-1.00) Johnson 2014 41 1 35 5 31 (86%) 1 0 7 23 20% 13 (0-53) 100 (85-100) 8.00 (0.36-178.93) 0.85 (0.63-1.15) Nikiforov 2014 143 2 141 143 (100%) 1 1 38 103 27% 3 (0-13) 99 (95-100) 2.67 (0.17-41.60) 0.98 (0.93-1.04) Poller 2014 11 0 11 6 (55%) 0 0 1 5 9% 0 (0-98) 100 (48-100) 3.00 (0.08-107.45) 0.82 (0.35-1.89) Seo 2014 13 1 12 13 (100%) 1 0 3 9 31% 25 (1-81) 100 (66-100) 6.00 (0.29-122.36) 0.74 (0.41-1.33) Giovanella 2015 61 0 61 61 (100%) 0 0 16 45 26% 0 (0-21) 100 (92-100) 2.71 (0.06-131.06) 0.98 (0.90-1.07) Park 2015 3 0 3 3 (100%) 0 0 1 2 33% 0 (0-98) 100 (16-100) 1.50 (0.05-49.07) 0.90 (0.35-2.32) Rossi 2015 37 4 33 17 (46%) 4 0 4 9 22% 50 (16-84) 100 (66-100) 10.00 (0.62-161.11) 0.53 (0.27-1.03) Beisa 2016 109 6 103 109 (100%) 6 0 17 86 21% 26 (10-48) 100 (96-100) 47.12 (2.75-807.16) 0.73 (0.57-0.94) Kowalska 2016 29 0 29 20 (69%) 0 0 2 18 7% 0 (0-84) 100 (81-100) 6.33 (0.15-262.92) 0.86 (0.51-1.43) Valderrabano 2016 58 0 58 37 (64%) 0 0 16 21 28% 0 (0-21) 100 (84-100) 1.29 (0.03-61.95) 0.99 (0.89-1.10) POOLED RESULTS 1,418 31 1,342 45 1,294 (94.2%) 30 1 338 925 26.0% 6.8 (3.0-14.8) 100 (97.8-100) 139.96 (2.30-8,518.26) 0.93 (0.88-0.99) FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and histopathological follow-up. ni: number of indeterminate thyroid nodules. test+: number of positive index tests. test-: number of negative index tests. test?: number of unknown or nondiagnostic index tests. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw